Pre-made Cusatuzumab benchmark antibody ( Whole mAb, anti-CD70/CD27-L therapeutic antibody, Anti-CD27L/LPFS3/CD27LG/TNFSF7/TNLG8A Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Cusatuzumab biosimilar, Whole mAb, Anti-CD70/CD27-L Antibody: Anti-CD27L/LPFS3/CD27LG/TNFSF7/TNLG8A therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
| Products Name (INN Index) | Pre-Made Cusatuzumab biosimilar, Whole mAb, Anti-CD70/CD27-L Antibody: Anti-CD27L/LPFS3/CD27LG/TNFSF7/TNLG8A therapeutic antibody |
|---|---|
| INN Name | Cusatuzumab |
| Target | CD70 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2017 |
| Year Recommended | 2018 |
| Companies | arGEN-X |
| Conditions Approved | NA |
| Conditions Active | Cutaneous T-cell lymphoma,Acute myeloid leukaemia,Haematological malignancies,Myelodysplastic syndromes,Solid tumours |
| Conditions Discontinued | Nasopharyngeal cancer,Autoimmune disorders |
| Development Tech | POTELLIGENT Technology;SIMPLE Antibody Technology |
| Previous Name | NA |
| Gm Offical Target Name | CD70/CD27-L |
| Package |
